(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Relive NASA's historic Artemis 2 launch to the moon in these stunning photos - 2Forum Dvorah demands clear support for women in combat as IDF gender debate escalates
- 3Senior's Manual for Obtaining a Hyundai Ioniq EV: Tips
- 4Flash flooding causes highways to close to and from Eilat
- 5Extreme Manual for Picking a Camper Van
- 6 Asian Urban areas to Visit
- Hand Skin Is Additionally Significant - What You Ought to Realize About Hand Cream
- Paraplegic engineer becomes the first wheelchair user to blast into space
- How did humans evolve, and will we evolve more?
- A Past filled with Old Civilizations: The World's Most established Societies
- NASA releases new ‘Earthset’ and eclipse images taken during historic flyby of the moon
- Nature's Best: A Manual for Beautiful Train Rides
- $2,000 tariff rebate checks? 50-year mortgages? Making sense of Trump's new 'affordability' proposals.
- Stolen Renoir, Cézanne and Matisse were probably uninsured, market sources say
